Pulmonx crashes to all-time low on dour FY outlook, Q3 revenue miss

Pulmonx

04/11/2022 16:36

** Shares of commercial-stage medical tech company Pulmonx
Corporation  LUNG.O  fall 59.4% at $5.01; stock trading at an
all-time low 
    ** LUNG cuts its FY22 rev. forecast to $51.5 mln-$52.5 mln
from $55 mln-$60 mln previously, below analyst's consensus
forecast of $53.7 mln, per IBES Refinitiv data
    ** Co reports Q3 rev. of $13.5 mln, falling below Wall
Street's consensus of $14.9 mln 
    ** LUNG suffered a loss of 38 cents/shr, compared with a
loss of 28 cents/shr a year earlier
    ** Majority of the seven brokerages covering the stock, 
rate it "hold"; their median PT is $16
    ** Stock has fallen 84.4% YTD compared with a ~34% decline
in the Nasdaq Composite index  .IXIC 
 (Reporting by Shashwat Chauhan in Bengaluru)
 ((Shashwat.Chauhan@thomsonreuters.com))